PRKAA2 and cardiomyopathy: In addition, Yang’s group found that FGF21 has physiological and pharmacological functions that prevent type 2 diabetic lipotoxicity-induced cardiomyopathy through activation of both AMPK/Akt2/Nrf2-mediated antioxidative pathway and AMPK/ACC/CPT-1-mediated lipid-lowering effect [15].